Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H ( (HK:1541) ) has issued an announcement.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has successfully completed the placement of 24.2 million new H shares, raising approximately HK$345.1 million. The proceeds will be used to fund research and development of cancer therapies, including IMM2510, IMM27M, and IMM01, as well as to replenish working capital and support general corporate purposes.
The most recent analyst rating on (HK:1541) stock is a Hold with a HK$11.50 price target. To see the full list of analyst forecasts on ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H stock, see the HK:1541 Stock Forecast page.
More about ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biopharmaceutical company based in China, focusing on the development of innovative cancer immunotherapies. The company is involved in research and development of treatments for solid tumors and other cancer-related therapies.
Average Trading Volume: 3,652,937
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.6B
See more data about 1541 stock on TipRanks’ Stock Analysis page.